Beyond Biotech - the podcast from Labiotech

Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma

July 22, 2022 Labiotech
Beyond Biotech - the podcast from Labiotech
Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma
Show Notes

On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify.

Poolbeg Pharma
, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza.

Biopharma company Mogrify Limited, and Japanese regenerative medicine firm Astellas Pharma Inc., have announced a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.

Belgian headquartered biotech Galapagos NV has acquired CellPoint and AboundBio, a move the Belgian company said propels it into next-generation cell therapy.

The deal saw the Lausanne-based team of US venture capital firm, +ND Capital, mark its second successful exit in the European biotech market.